Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Median Effective Dose of Remimazolam for Duodenoscopy Insertion During ERCP With Alfentanil 10µg/kg

NCT04969068 is registered in ClinicalTrials.gov with Tianjin Nankai Hospital as lead sponsor.

NCT NCT04969068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04969068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Median Effective Dose of Remimazolam for Duodenoscopy Insertion During ERCP With Alfentanil 10µg/kg
Lead sponsor
Tianjin Nankai Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
July 23, 2021
Completion date
December 30, 2021
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anesthesia